Investment Focus
The Full Stack of AI-Driven Medicine.
We invest across three interconnected layers of the AI therapeutics stack — from the earliest moments of target identification to the final stages of clinical execution.
Discovery Technology
Finding what was previously unfindable.
Overview
The drug discovery process has historically been defined by its failure rate. LJL Ventures backs companies that are fundamentally changing those odds — using AI to identify novel targets, design molecules with precision, and compress the timeline from hypothesis to validated hit.
Our Thesis
We believe the next generation of medicines will be discovered by machines working alongside scientists — not by chance, but by design. The companies we back are building the computational infrastructure that makes this possible at scale.
What We Back
Target Identification & Validation
AI-driven analysis of multi-omic datasets to surface novel, high-confidence therapeutic targets across disease areas.
Molecular Design & Optimization
Generative models for small molecules, peptides, and biologics that explore chemical space far beyond traditional methods.
RNA Therapeutics Platforms
Computational design of siRNA, mRNA, and antisense oligonucleotides with optimized delivery and efficacy profiles.
Structure-Based Drug Design
Deep learning models that predict protein structure, binding affinity, and ADMET properties with high accuracy.
Example Investment Thesis
A platform company using foundation models trained on protein-ligand interaction data to design first-in-class small molecules for previously undruggable targets.
Development Technology
Compressing the path from IND to proof of concept.
Overview
Between a validated hit and a clinical candidate lies one of the most expensive and failure-prone stretches in drug development. LJL Ventures invests in platforms that use AI and data infrastructure to de-risk this phase — accelerating IND-enabling studies, improving biomarker selection, and building the data assets that inform every downstream decision.
Our Thesis
Development-stage attrition is not inevitable. The companies we back treat IND-enabling work as a data generation exercise — building proprietary datasets and predictive models that compound in value across every program they run.
What We Back
Predictive ADMET & Safety
Machine learning models that predict absorption, distribution, metabolism, excretion, and toxicity early — before costly in vivo studies.
Biomarker Discovery
AI-powered analysis of clinical and preclinical data to identify patient stratification biomarkers and pharmacodynamic endpoints.
Formulation & Delivery Optimization
Computational tools for optimizing drug delivery systems, including lipid nanoparticles, conjugates, and targeted delivery platforms.
Regulatory Intelligence
NLP and knowledge graph systems that synthesize regulatory precedent to inform IND strategy and CMC development.
Example Investment Thesis
A data infrastructure company that aggregates and harmonizes preclinical datasets across modalities, enabling predictive models that reduce IND-enabling timelines by 40%.
Clinical Technology
Improving the probability of regulatory success.
Overview
Clinical trials remain the single largest cost center and failure point in drug development. LJL Ventures backs companies that apply AI to real-world data, digital biomarkers, and adaptive trial design to improve the probability that promising drugs reach patients.
Our Thesis
The clinical trial of the future will be smaller, faster, and more informative than today's. The companies we back are building the tools that make adaptive, data-rich, patient-centric trials the standard — not the exception.
What We Back
Adaptive Trial Design
AI-powered platforms for designing and executing adaptive clinical trials that respond to accumulating data in real time.
Real-World Data & Evidence
Systems that curate, harmonize, and analyze real-world data to support regulatory submissions and post-market surveillance.
Digital Biomarkers & Endpoints
Wearable and sensor-derived biomarkers validated as regulatory endpoints, enabling remote and decentralized trials.
Patient Identification & Recruitment
AI-driven patient matching and site selection tools that reduce recruitment timelines and improve trial diversity.
Example Investment Thesis
A clinical intelligence platform that uses federated learning across hospital networks to identify eligible patients and predict trial outcomes before enrollment closes.
Portfolio Advantage
The LJL Foundry
Every LJL Ventures company plugs into a common pool of data resources and AI models. Results feed back to strengthen the platform for all — compounding the advantage of every company in the portfolio.
Shared Data Resources
Portfolio companies contribute proprietary datasets to a growing shared repository, giving every company access to richer training data than any single company could build alone.
Shared AI Models
Foundation models fine-tuned across therapeutic areas are available to all portfolio companies, accelerating development timelines and reducing duplicated infrastructure spend.
Two-Way Access
Companies draw on shared resources and contribute results back — creating a compounding flywheel that strengthens the platform with every new dataset and model iteration.
Fund Overview
Download our overview document for a detailed look at our investment thesis, focus areas, and approach.
Building in one of these areas?
We invest at pre-seed through Series A. If you're working on AI-driven therapeutics technology, we want to hear from you.